JPM重磅關注 | 2026中國FIC創新與合作峰會

——掃描上方二維碼，報名參會—

過去十年，中國創新藥研發管線數量呈現爆發式增長，已成為全球新藥研發體系中不可或缺的一環。在雙特異性抗體、ADC等前沿技術領域，中國已形成具備全球競爭力的研發集群，持續推動跨境交易活躍增長。2025年，中國創新藥對外許可總額突破1000億美元，達2024年同期的兩倍。然而，目前僅有約10%的新藥管線進入交易視野，更多高價值資產仍待全球合作伙伴共同發掘。

中國創新藥的崛起并非偶然，而是政策引導、人才集聚、資本支持與產業升級共同驅動的必然結果。這一體系性優勢，使中國在新藥研發效率、臨床執行能力及前沿賽道布局方面展現出卓越潛力。

在此關鍵歷史時刻，）肩負使命，將于2026年JPM大會期間，隆重主辦“2026中國FIC創新與合作峰會” 。這不僅僅是一場會議，更是一次中國生物科技力量的集體亮相，一個為全球伙伴精心打造的頂級合作平臺。

本屆峰會將系統解讀中國創新藥的發展動因、現狀與未來趨勢，并精選一批在全球范圍內具有領先研發進度、高度臨床契合度及顯著交易價值的創新藥項目進行路演，為與會者提供評估中國創新實力、發掘高價值合作機遇的重要窗口。

主辦機構：ZFIC聯盟

時間：2026年1月11日

地點：美國加州舊金山市中心凱悅酒店

會議人數：400人

參會形式：免費報名+審核、邀約

—會議酒店掠影—

活動日程

Event Agenda

09:00-09:20 致辭

09:20-09:40主題演講

從監管視角看中國生物醫藥創新的演變歷程

李自力 博士，國際藥物信息協會（DIA）全球董事，ZFIC聯盟戰略顧問

09:40-10:20主題演講

中國生物科技創新的全球趨勢

10:10-10:20 茶歇

自由交流

10:20-10:40 主題演講

中國創新藥對外授權交易趨勢與數據洞察

李昕欣，醫藥魔方海外市場首席顧問

10:40-11:00 主題演講

小核酸創新藥的中國力量

鐘輝，堯景基因首席科學家

11:00-12:00圓桌討論

中國FIC管線的創新前沿展望

12:00-13:00 自助午餐

13:10-13:20 ZFIC聯盟介紹

13:20-13:40主題演講

創新藥生態的“通關指南”：人才、政策與資本的高效協同

13:40-14:00 主題演講

高質量臨床試驗支持原創藥物開發：全球首款心肌梗死抗體藥物SGC001的實踐

孟玲，舜景醫藥副總經理

14:00-16:30 項目路演

• Targeting GSDME: A First-in-Class Mechanism to Block Inflammatory Neuronal Death in ALS and Beyond

  炎明生物

• KN060, A phase II stage potential BIC anti-FXI bispecific antibody

  康寧杰瑞

• A Potential First-in-Class Bispecific Antibody as A Backbone Immunotherapy

  熱景生物

• JV101: Redefining Heart Failure Treatment with a One-Time, Broadly Effective Gene Therapy

  愈方生物

• FL115: A Next-Generation Engineered IL-15 Therapy Designed for Streamlined Efficacy and Optimal Synergy in Combination Immunotherapy

  復融生物

• KC1086: A First-in-Class and Differentiated Dual KAT6/7 Inhibitor with Superior Preclinical Profile for Resistant ER+ Breast Cancer

  康辰藥業

• NouvNeu001:the 1st chemical derived cell therapeutic product in the World

  睿健醫藥

• YN001: An Actively Targeted Therapy Demonstrating Direct Atherosclerotic Plaque Regression in Clinical Trials

  茵諾醫藥

• GS1191: A Potentially Best-in-Class Hemophilia A Gene Therapy with Superior Efficacy at a lower Dose

  華毅樂健

16:30-17:15圓桌討論

尋找下一個重磅藥物：立項、速度與價值

17:15-18:00圓桌討論

攜手向前：構建創新藥全球新生態

活動亮點

Event Highlights

中國創新生態系統全景透視：FIC創新藥戰略發展聯盟（ZFIC Alliance）首次海外亮相，從監管視角解讀中國創新生態系統質變，以數據呈現中國創新藥管線版圖和跨境交易趨勢，幫助海外藥企和投資機構更加系統深入地理解中國創新藥產業。

高質量國際交流：參會觀眾中，海外公司占比70%，國內公司30%。藥企VP以上管理層和機構合伙人占比70%，云集 輝瑞、葛蘭素史克、吉利德、 拜耳、 默克、武田制藥、 百濟神州、 復宏漢霖、恒瑞醫藥、科倫博泰、RA Capital等知名藥企和投資機構。

高潛力項目路演：ZFIC聯盟專家組從近30個申報公司項目中優選8個匹配臨床未滿足需求、具有較高創新水平且研發進度領先、具有FIC和BIC成藥潛力的代表性中國創新藥項目，進行現場路演，幫助海外藥企和投資機構更高效地發掘中國創新藥優質資產。

—掃碼報名參會—

2026 China FIC Innovation and

Collaboration Summit

Over the past decade, the number of innovative drug pipelines in China has experienced explosive growth and has become an important part of the global innovative drug landscape. In the meanwhile, transaction activities over Chinese innovative drugs have continued to be active, with cross-border transactions emerging continuously. In particular, China has formed R&D clusters with global competitiveness in emerging technology fields such as bispecific antibodies and ADCs. In 2025, the total amount of cross-border licensing of Chinese innovative drugs exceeded 100 billion US dollars, doubling the scale of the same period in 2024. Even so, only about 10% of the new drug pipelines in China have been involved in transactions. More high-value tradable pipeline assets are still waiting to be explored for cooperation with global partners.

In light of this, the FIC Innovative Drug Strategic Development Alliance (ZFIC Alliance) will hold the "2026 China FIC Innovation and Collaboration Summit" during the 2026 JPM Conference, aiming to build an efficient communication platform for international pharmaceutical companies, investment institutions, and Chinese biotech enterprises.

This summit will provide a comprehensive data-driven interpretation of driving factors, current status, and future trends of Chinese innovative drugs’ explosive growth, and offering participants a full and authentic view of the Chinese innovative drug landscape. In addition, the summit will organize roadshows for a number of selected Chinese innovative drug pipelines of globally leading development status, critical clinical relevance, and significant underlying transaction values. The event will be a window to discover high-value strategic cooperation opportunities over China's most innovative therapeutic assets.

Time: January 11, 2026

Venue: Hyatt Regency San Francisco Downtown SOMA

Agenda

8:30-9:00 Registration

9:00-9:20 Opening Remarks

9:20-9:50 Keynote Speech

Understanding the Evolution of China’s Biotech Innovation: A Regulatory Perspective

Zili Li, MD MPH，DIA Fellow and Board Member Strategic Advisor to ZFIC Alliance

9:50-10.10 Keynote Speech

Trends in China's Biotech Innovation

10:10-10:20 Coffee Break

10:20-10:40 Keynote Speech

Trends and Data Insights of China's Innovative Drug Out-Licensing Transactions

Xinxin Li，Principal Advisor, Pharmcube

10:40-11:00 Keynote Speech

Highlights of China’s innovation in Oligonucleotide Innovative Drugs

Dr. Joann Zhong, CSO, Beijing Youngen Biotechnology Co., Ltd.

11:00-12:00 Panel Discussion

Outlook of China's FIC Pipeline

12:00-13:20 Buffet Lunch

13:20-13:40 Keynote Speech

The "Rulebook" for the Innovative Drug Ecosystem: Efficient Synergy of Talent, Policy, and Capital

13:40-14:00 Keynote Speech

High-Quality Clinical Trials Underpinning Innovative Drug Development: Development of SGC001, the First-in-World Antibody for Myocardial Infarction

Dr. Ling Meng, Vice President, Beijing Sungen Biomedical Technology Co., Ltd.

14:00-16:30 Roadshow

• Targeting GSDME: A First-in-Class Mechanism to Block Inflammatory Neuronal Death in ALS and Beyond

  Pyrotech Therapeutics

• KN060, A phase II stage potential BIC anti-FXI bispecific antibody

  Suzhou Alphamab Co., Ltd.

• A Potential First-in-Class Bispecific Antibody as A Backbone Immunotherapy

  Hotgen

• JV101: Redefining Heart Failure Treatment with a One-Time, Broadly Effective Gene Therapy

  Shanghai Yufang Biopharmaceutical Technology

• FL115: A Next-Generation Engineered IL-15 Therapy Designed for Streamlined Efficacy and Optimal Synergy in Combination Immunotherapy

  Forlong Biotech

• KC1086: A First-in-Class and Differentiated Dual KAT6/7 Inhibitor with Superior Preclinical Profile for Resistant ER+ Breast Cancer

  Beijing Konruns Pharmaceutical

• NouvNeu001:the 1st chemical derived cell therapeutic product in the World

• iRegene Therapeutics

• YN001: An Actively Targeted Therapy Demonstrating Direct Atherosclerotic Plaque Regression in Clinical Trials

• Beijing Inno Medicine Co., Ltd.

• GS1191: A Potentially Best-in-Class Hemophilia A Gene Therapy with Superior Efficacy at a lower Dose

• Gritgen Therapeutics

16:30-17:15 Panel Discussion

Finding the Next Blockbuster Drug: Project Planning, Speed, and Value

17:15-18:00 Panel Discussion

Moving Forward Together: Building a New Global Ecosystem for Innovative Drugs